HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jack G. Copeland Francisco A. Arabia Gulshan K. Sethi Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Copeland, J. G. Articles by Banchy, M. E. Search for Related Content PubMed PubMed Citation Articles by Copeland, J. G. Articles by Banchy, M. E.

Ann Thorac Surg 1999;68:756-760
© 1999 The Society of Thoracic Surgeons

---

Patient Management And Device Selection For Long-Term Support

Arizona experience with CardioWest total artificial heart bridge to transplantation

^a University of Arizona Health Sciences Center, Tucson, Arizona, USA

Address reprint requests to Dr Copeland, Cardiovascular and Thoracic Surgery, The University of Arizona Health Sciences Center, 1501 N. Campbell Ave, Rm 4402, Tucson, AZ 85724
e-mail: jgcbriez{at}aol.com

Presented at the Fourth International Conference on Circulatory Support Devices for Severe Cardiac Failure, Houston, TX, Oct 3–5, 1997.

Abstract

Background. We hypothesized that bridge to transplantation with the CardioWest Total Artificial Heart would succeed in a large percentage of patients. Further, we hypothesized that this success rate would not be significantly decreased by infection or thromboembolism.

Methods. From 1993 to March 1999, 24 patients received implants with the intention of bridge to transplantation. Data were collected prospectively. Heparin, coumadin, aspirin, ticlopidine, dipyridamole, and pentoxifylline were used for anticoagulation.

Results. Four patients died while on device support. Nineteen of 23 patients (83%) were transplanted. All 19 survived long term. One patient remains on CardioWest Total Artificial Heart support 6 weeks after implant. There was one stroke on the day of transplantation. There was a second stroke on the day of implantation. Neither stroke caused significant residual deficits. Both were in close relationship to an operative procedure. There were no serious device-related infections.

Conclusions. The CardioWest Total Artificial Heart salvaged 20 of 24 critically ill patients. Neither infections nor neurologic problems were significant. We believe it is the device of choice for decompensating patients with biventricular failure who have adequate body and heart size.

This article has been cited by other articles:

				J. G. Copeland, R. G. Smith, R. K. Bose, P. H. Tsau, P. E. Nolan, and M. J. Slepian Risk factor analysis for bridge to transplantation with the CardioWest total artificial heart. Ann. Thorac. Surg., May 1, 2008; 85(5): 1639 - 1644. [Abstract] [Full Text] [PDF]

				J. G. Copeland, R. G. Smith, F. A. Arabia, P. E. Nolan, G. K. Sethi, P. H. Tsau, D. McClellan, M. J. Slepian, and the CardioWest Total Artificial Heart Investigator Cardiac Replacement with a Total Artificial Heart as a Bridge to Transplantation N. Engl. J. Med., August 26, 2004; 351(9): 859 - 867. [Abstract] [Full Text] [PDF]

				D. H. Delgado, V. Rao, H. J. Ross, S. Verma, and N. G. Smedira Mechanical Circulatory Assistance: State of Art Circulation, October 15, 2002; 106(16): 2046 - 2050. [Full Text] [PDF]